Date published: 2025-10-15

1-800-457-3801

SCBT Portrait Logo
Seach Input

ATXN7L3B Inhibitors

ATXN7L3B inhibitors are a class of chemical compounds that specifically inhibit the activity of the ATXN7L3B (ataxin-7-like 3B) protein. ATXN7L3B, closely related to ATXN7L3, is a component of multiprotein complexes involved in transcriptional regulation and chromatin modification. Like its homolog, ATXN7L3B participates in histone deubiquitination, a key process in the regulation of chromatin structure and gene expression. Histone ubiquitination and deubiquitination are critical for maintaining the proper organization of chromatin and ensuring the appropriate expression of genes. ATXN7L3B inhibitors are designed to block the protein's ability to interact with other subunits of these complexes, thereby disrupting its role in modifying chromatin and influencing transcriptional activity.

The use of ATXN7L3B inhibitors provides researchers with tools to explore how this protein specifically contributes to the regulation of gene expression and chromatin remodeling. By inhibiting ATXN7L3B, scientists can study how changes in histone deubiquitination affect the overall chromatin landscape and the downstream impacts on transcriptional regulation. These inhibitors help to delineate the unique roles of ATXN7L3B in contrast to its homologs or other components of chromatin-modifying complexes, offering deeper insights into the specificity of chromatin modification pathways. Additionally, studying ATXN7L3B inhibitors enhances the understanding of how alterations in chromatin structure can influence cellular processes such as differentiation, development, and response to environmental signals. These inhibitors are important tools for investigating the complex regulatory networks that govern chromatin dynamics and gene expression, providing a window into the intricate machinery that controls epigenetic modifications within the cell.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Inhibits PI3K, potentially affecting downstream signaling that intersects with ATXN7L3B.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

Inhibits PI3K, potentially altering pathways that could intersect with ATXN7L3B activity.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

Selectively inhibits MEK, which could impact MAPK/ERK signaling related to ATXN7L3B.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

Inhibits MEK, potentially affecting MAPK/ERK signaling pathways associated with ATXN7L3B.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

Inhibits p38 MAP kinase, which can modulate pathways potentially connected to ATXN7L3B.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

Inhibits JNK, potentially influencing signaling pathways that could affect ATXN7L3B.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Inhibits mTOR, which can alter signaling pathways potentially related to ATXN7L3B.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

Proteasome inhibitor, potentially affecting protein turnover related to ATXN7L3B interactions.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$149.00
$470.00
$620.00
$1199.00
$2090.00
33
(3)

Inhibits histone deacetylase, possibly affecting gene expression related to ATXN7L3B.

Thapsigargin

67526-95-8sc-24017
sc-24017A
1 mg
5 mg
$94.00
$349.00
114
(2)

Inhibits SERCA, potentially affecting calcium signaling related to ATXN7L3B.